CommentNew option for primary stroke prevention in sickle cell anaemia
References (9)
- et al.
Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results
Blood
(2006) - et al.
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
Lancet
(2015) Big strokes in small persons
Arch Neurol
(2007)- et al.
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
N Engl J Med
(1998)
There are more references available in the full text version of this article.
Cited by (3)
Sickle cell disease: Clinical presentation and management of a global health challenge
2019, Blood ReviewsCitation Excerpt :The multicentre TCD With Transfusion Changing to Hydroxyurea trial (TWiTCH) demonstrated that for a subset of patients with sickle cell disease who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxyurea is an effective alternative to transfusions [132]. However, long-term follow-up data are needed to define the long-term benefits of hydroxyurea therapy [133,134]. Acute chest syndrome is the second most common cause of hospital admissions in patients with sickle cell disease [39].
Neurologic complications of sickle cell disease in Africa
2017, NeurologyEffectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome
2017, Journal of Neurosurgery: Pediatrics
Copyright © 2016 Elsevier Ltd. All rights reserved.